← 홈

흑색종

106개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 106개
AntibodystaleXencor, Inc.Phase 2

XmAb20717 (XmAb20717)

Biliary Tract Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
임상시험 9상태 RECRUITING
ADCBiologicstaleCelldex TherapeuticsPreclinical

glembatumumab vedotin (glembatumumab vedotin)

Metastatic gpNMB Expressing Triple Negative Breast Cancer · Melanoma

#Melanoma#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 21%임상시험 9상태 ACTIVE
CGTBiologicstaleMiltenyi Biomedicine GmbHPhase 2

MB-CART19.1 (MB-CART19.1)

Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory · Melanoma Stage III

#MelanomaStageIII#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 7상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab Injection [Opdivo])

Advanced Cancer; Gastric Cancer · Malignant Melanoma

#MalignantMelanoma#Antibody#Phase2#항체#면역항체+4
임상시험 7상태 RECRUITING
CGTBiologicstaleTILT Biotherapeutics Ltd.Phase 2

TILT-123 (TILT-123)

Melanoma; Head and Neck Squamous Cell Carcinoma · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 6상태 RECRUITING
AntibodyJanssenPhase 2

Amivantamab + FOLFIRI (Amivantamab + FOLFIRI)

RAS/BRAF Wild-type Advanced Colorectal Cancer Patients · RAS/BRAF Wild-type Advanced Colorectal C

#RASBRAFWild-typeAdvancedColorect#Antibody#Phase2#항체#면역항체+4
임상시험 4상태 RECRUITING
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

Anti-NY ESO-1 T-cell receptor PBL (Anti-NY ESO-1 T-cell receptor PBL)

Metastatic Melanoma; Metastatic Renal Cell Cancer · Metastatic Melanoma

#MetastaticMelanoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 3상태 DISCONTINUED
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

autologous anti-MART-1 F5 T-cell receptor (autologous anti-MART-1 F5 T-cell receptor)

Melanoma; Skin Cancer · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 3상태 ACTIVE
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes (autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes)

Melanoma · Metastatic Melanoma

#MetastaticMelanoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 3상태 DISCONTINUED
AntibodystaleBristol Myers SquibbPhase 2

HF10 plus Ipilimumab (HF10 plus Ipilimumab)

Malignant Melanoma · Malignant Melanoma

#MalignantMelanoma#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 3

nivolumab (Opdivo, Nivolumab/rHuPH20)

Melanoma · Melanoma

#Melanoma#Antibody#Phase3#항체#면역항체+2
효능 ORR 0%임상시험 2상태 DISCONTINUED
CGTBiologicstaleInge Marie SvanePhase 1

ADP-TILIL7 (ADP-TILIL7)

Melanoma Stage III; Melanoma Stage IV · Melanoma Stage III

#MelanomaStageIII#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing Immunochina Medical Sci…Phase 2

AMT-116 CAR-T cells (AMT-116 CAR-T cells)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleBeijing Immunochina Medical Sci…Phase 2

AMT-253 CAR-T cells (AMT-253 CAR-T cells)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
AntibodystaleThe Netherlands Cancer InstitutePhase 3

nivolumab (Opdivo, Adjuvant nivolumab)

Malignant Melanoma Stage III · Malignant Melanoma Stage III

#MalignantMelanomaStageIII#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
CGTBiologicstaleErasmus Medical CenterPhase 2

Adoptive therapy with autologous MC2 TCR T cells (Adoptive therapy with autologous MC2 TCR T cells)

Melanoma; Melanoma, Uveal · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

Anti-NY ESO-1 T cell receptor (TCR, Anti-NY ESO-1 T cell receptor, Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells)

Metastatic Cancer; Metastatic Melanoma · Metastatic Cancer

#MetastaticCancer#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 4%임상시험 1상태 DISCONTINUED
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

Anti-NY ESO-1 mTCR PBL (Anti-NY ESO-1 mTCR PBL)

Melanoma; Meningioma · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

Anti-VEGFR2 CAR CD8 plus PBL (Anti-VEGFR2 CAR CD8 plus PBL)

Metastatic Cancer; Metastatic Melanoma · EGFR

#EGFR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED
CGTBiologicShenzhen Geno-Immune Medical In…Phase 2

Antigen-specific CAR T, CTL and DCvac to treat melanoma. (Antigen-specific CAR T, CTL and DCvac to treat melanoma.)

Melanoma · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING

2 / 6 페이지

← 이전다음 →